HUE051390T2 - Háromszegmensû arenavírusok mint vakcinavektorok - Google Patents
Háromszegmensû arenavírusok mint vakcinavektorokInfo
- Publication number
- HUE051390T2 HUE051390T2 HUE15794900A HUE15794900A HUE051390T2 HU E051390 T2 HUE051390 T2 HU E051390T2 HU E15794900 A HUE15794900 A HU E15794900A HU E15794900 A HUE15794900 A HU E15794900A HU E051390 T2 HUE051390 T2 HU E051390T2
- Authority
- HU
- Hungary
- Prior art keywords
- arenaviruses
- segment
- vaccine vectors
- vaccine
- vectors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
- C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10061—Methods of inactivation or attenuation
- C12N2760/10062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/80—Vectors comprising a special translation-regulating system from vertebrates
- C12N2840/85—Vectors comprising a special translation-regulating system from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462079493P | 2014-11-13 | 2014-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE051390T2 true HUE051390T2 (hu) | 2021-03-01 |
Family
ID=54545130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15794900A HUE051390T2 (hu) | 2014-11-13 | 2015-11-12 | Háromszegmensû arenavírusok mint vakcinavektorok |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10722564B2 (enExample) |
| EP (2) | EP3778903A1 (enExample) |
| JP (4) | JP6805139B2 (enExample) |
| CN (1) | CN107223130A (enExample) |
| AU (3) | AU2015345080B2 (enExample) |
| CA (1) | CA2967720C (enExample) |
| CY (1) | CY1123339T1 (enExample) |
| DK (1) | DK3218504T3 (enExample) |
| ES (1) | ES2811093T3 (enExample) |
| HR (1) | HRP20201684T1 (enExample) |
| HU (1) | HUE051390T2 (enExample) |
| LT (1) | LT3218504T (enExample) |
| PL (1) | PL3218504T3 (enExample) |
| PT (1) | PT3218504T (enExample) |
| RS (1) | RS60937B1 (enExample) |
| SI (1) | SI3218504T1 (enExample) |
| WO (1) | WO2016075250A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20221475T3 (hr) | 2007-12-27 | 2023-01-06 | Universität Zürich | Replikacijski defektni vektori arenavirusa |
| LT3077519T (lt) | 2013-12-03 | 2021-04-26 | Hookipa Biotech Gmbh | Cmv vakcinos |
| RS60937B1 (sr) | 2014-11-13 | 2020-11-30 | Univ Geneve | Tri-segmentirani arenavirusi kao vektori za vakcinu |
| JP7098330B2 (ja) * | 2015-06-10 | 2022-07-11 | ホオキパ バイオテック ジーエムビーエイチ | Ｈｐｖワクチン |
| WO2018045029A1 (en) * | 2016-09-02 | 2018-03-08 | The United States Of America, As Represented By The Secretary Of The Army | Pan south american arenavirus live attenuated vaccine |
| ES2934698T3 (es) * | 2015-11-04 | 2023-02-24 | Hookipa Biotech Gmbh | Vacunas contra el virus de la hepatitis B |
| CA3003548A1 (en) * | 2015-11-12 | 2017-05-18 | Hookipa Biotech Ag | Arenavirus particles as cancer vaccines |
| EP3534943A2 (en) * | 2016-11-04 | 2019-09-11 | Hookipa Biotech GmbH | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| WO2018185307A1 (en) | 2017-04-07 | 2018-10-11 | Hookipa Biotech Ag | Arenavirus particles to treat solid tumors |
| US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
| CN108611310A (zh) * | 2018-04-28 | 2018-10-02 | 中国药科大学 | 一种重组Hsp65与STEAP1186-193融合蛋白的基因工程菌的构建 |
| CN108977434A (zh) * | 2018-07-03 | 2018-12-11 | 张罗 | 鼻腔脱落细胞rna的提取方法 |
| AU2020297011A1 (en) * | 2019-06-18 | 2022-02-10 | Janssen Sciences Ireland Unlimited Company | Arenavirus vectors for hepatitis B virus (HBV) vaccines and uses thereof |
| US11795210B2 (en) | 2019-07-16 | 2023-10-24 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| LT4037708T (lt) | 2019-09-30 | 2024-11-25 | Gilead Sciences, Inc. | Hbv vakcinos ir hbv gydymo būdai |
| US20220380805A1 (en) * | 2019-11-07 | 2022-12-01 | Universität Basel | Arenaviruses as vectors |
| AU2021282287A1 (en) | 2020-05-29 | 2023-01-05 | Hookipa Biotech Gmbh | Cancer treatment strategies using arenavirus vectors |
| JP7693813B2 (ja) | 2021-01-14 | 2025-06-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン及び使用方法 |
| WO2022159664A1 (en) * | 2021-01-22 | 2022-07-28 | Chan Zuckerberg Biohub, Inc. | Engineered multi-segmented rna viruses for large-scale combinatorial genetic screening |
| US20240174724A1 (en) | 2021-03-23 | 2024-05-30 | Hookipa Biotech Gmbh | Arenaviruses used in treatments of prostate cancer |
| US20240229073A1 (en) | 2021-05-13 | 2024-07-11 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
| JP2024540385A (ja) | 2021-11-08 | 2024-10-31 | ホオキパ バイオテック ジーエムビーエイチ | 変異型ｋｒａｓ、変異したがんドライバー遺伝子、または腫瘍関連抗原を発現する、がん免疫療法としての改変アレナウイルス粒子 |
| CN114231562A (zh) * | 2021-12-15 | 2022-03-25 | 中国科学院武汉病毒研究所 | 一种表达荧光素酶基因的淋巴脉络丛脑膜炎病毒及其构建方法和应用 |
| WO2023152116A1 (en) | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences Inc | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| WO2025056782A1 (en) | 2023-09-15 | 2025-03-20 | Hookipa Biotech Gmbh | Arenavirus formulations, methods and uses thereof |
| WO2025191169A1 (en) | 2024-03-15 | 2025-09-18 | Hookipa Biotech Gmbh | Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US8158413B2 (en) * | 2005-10-17 | 2012-04-17 | Institut Pasteur | Lentiviral vector-based vaccine |
| EP2010537B1 (en) | 2006-03-23 | 2011-12-28 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
| US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
| HRP20221475T3 (hr) | 2007-12-27 | 2023-01-06 | Universität Zürich | Replikacijski defektni vektori arenavirusa |
| GB201001726D0 (en) * | 2010-02-03 | 2010-03-24 | Univ St Andrews | Bunyavirus vaccine |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| IN2014DN06118A (enExample) | 2012-01-24 | 2015-08-14 | Sanford Res Usd | |
| EP2968506B1 (en) | 2013-03-15 | 2019-07-31 | Université de Genève | Anti-mycobacterial vaccines |
| GB201305361D0 (en) | 2013-03-25 | 2013-05-08 | Univ Edinburgh | Enhanced expression |
| LT3077519T (lt) | 2013-12-03 | 2021-04-26 | Hookipa Biotech Gmbh | Cmv vakcinos |
| WO2015183895A1 (en) | 2014-05-27 | 2015-12-03 | University Of Rochester | Novel arenavirus vaccine |
| US9943585B2 (en) | 2014-07-30 | 2018-04-17 | University Of Rochester | Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV) |
| JP6875274B6 (ja) | 2014-09-22 | 2021-06-30 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | ピチンデウイルスのリバースジェネティクス系及び使用方法 |
| GB201419572D0 (en) | 2014-11-03 | 2014-12-17 | Pirbright Inst The | Virus |
| RS60937B1 (sr) | 2014-11-13 | 2020-11-30 | Univ Geneve | Tri-segmentirani arenavirusi kao vektori za vakcinu |
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| JP7098330B2 (ja) | 2015-06-10 | 2022-07-11 | ホオキパ バイオテック ジーエムビーエイチ | Ｈｐｖワクチン |
| ES3021881T3 (en) | 2015-10-23 | 2025-05-27 | Pasteur Institut | Recombinant mopeia virus and vaccine platform |
| ES2934698T3 (es) | 2015-11-04 | 2023-02-24 | Hookipa Biotech Gmbh | Vacunas contra el virus de la hepatitis B |
| CA3003548A1 (en) | 2015-11-12 | 2017-05-18 | Hookipa Biotech Ag | Arenavirus particles as cancer vaccines |
| KR20240095333A (ko) | 2016-05-18 | 2024-06-25 | 유니버시타트 바셀 | 백신 벡터로서 3개의 세그먼트를 가진 피친드 바이러스 |
| EP3534943A2 (en) | 2016-11-04 | 2019-09-11 | Hookipa Biotech GmbH | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| WO2018185307A1 (en) | 2017-04-07 | 2018-10-11 | Hookipa Biotech Ag | Arenavirus particles to treat solid tumors |
-
2015
- 2015-11-12 RS RS20201251A patent/RS60937B1/sr unknown
- 2015-11-12 LT LTEP15794900.9T patent/LT3218504T/lt unknown
- 2015-11-12 PL PL15794900T patent/PL3218504T3/pl unknown
- 2015-11-12 EP EP20184468.5A patent/EP3778903A1/en active Pending
- 2015-11-12 JP JP2017525893A patent/JP6805139B2/ja active Active
- 2015-11-12 SI SI201531397T patent/SI3218504T1/sl unknown
- 2015-11-12 PT PT157949009T patent/PT3218504T/pt unknown
- 2015-11-12 CA CA2967720A patent/CA2967720C/en active Active
- 2015-11-12 HR HRP20201684TT patent/HRP20201684T1/hr unknown
- 2015-11-12 EP EP15794900.9A patent/EP3218504B1/en active Active
- 2015-11-12 CN CN201580073235.6A patent/CN107223130A/zh active Pending
- 2015-11-12 ES ES15794900T patent/ES2811093T3/es active Active
- 2015-11-12 US US15/526,211 patent/US10722564B2/en active Active
- 2015-11-12 HU HUE15794900A patent/HUE051390T2/hu unknown
- 2015-11-12 WO PCT/EP2015/076458 patent/WO2016075250A1/en not_active Ceased
- 2015-11-12 DK DK15794900.9T patent/DK3218504T3/da active
- 2015-11-12 AU AU2015345080A patent/AU2015345080B2/en active Active
-
2020
- 2020-07-07 US US16/922,489 patent/US20210145950A1/en not_active Abandoned
- 2020-09-16 CY CY20201100879T patent/CY1123339T1/el unknown
- 2020-12-03 JP JP2020201083A patent/JP2021045154A/ja active Pending
-
2022
- 2022-01-06 AU AU2022200061A patent/AU2022200061A1/en not_active Abandoned
-
2023
- 2023-01-05 JP JP2023000345A patent/JP2023036933A/ja active Pending
- 2023-11-13 US US18/507,584 patent/US20240082376A1/en active Pending
-
2024
- 2024-11-06 AU AU2024259760A patent/AU2024259760A1/en active Pending
-
2025
- 2025-08-21 JP JP2025138430A patent/JP2025170342A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10722564B2 (en) | 2020-07-28 |
| AU2015345080A1 (en) | 2017-06-01 |
| EP3778903A1 (en) | 2021-02-17 |
| JP2025170342A (ja) | 2025-11-18 |
| AU2024259760A1 (en) | 2024-11-28 |
| JP2017535267A (ja) | 2017-11-30 |
| WO2016075250A1 (en) | 2016-05-19 |
| JP2023036933A (ja) | 2023-03-14 |
| AU2022200061A1 (en) | 2022-02-03 |
| US20240082376A1 (en) | 2024-03-14 |
| SI3218504T1 (sl) | 2020-11-30 |
| EP3218504A1 (en) | 2017-09-20 |
| JP6805139B2 (ja) | 2020-12-23 |
| US20210145950A1 (en) | 2021-05-20 |
| EP3218504B1 (en) | 2020-07-22 |
| LT3218504T (lt) | 2020-09-10 |
| PT3218504T (pt) | 2020-09-24 |
| CA2967720C (en) | 2024-01-02 |
| HK1244034A1 (en) | 2018-07-27 |
| HRP20201684T1 (hr) | 2020-12-25 |
| CA2967720A1 (en) | 2016-05-19 |
| US20170319673A1 (en) | 2017-11-09 |
| CY1123339T1 (el) | 2021-12-31 |
| JP2021045154A (ja) | 2021-03-25 |
| RS60937B1 (sr) | 2020-11-30 |
| ES2811093T3 (es) | 2021-03-10 |
| DK3218504T3 (da) | 2020-10-19 |
| AU2015345080B2 (en) | 2022-01-27 |
| PL3218504T3 (pl) | 2021-02-08 |
| CN107223130A (zh) | 2017-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE051390T2 (hu) | Háromszegmensû arenavírusok mint vakcinavektorok | |
| NO2023036I1 (no) | Somatrogen | |
| DK3393510T3 (da) | Zikavirusvaccine | |
| LT3134402T (lt) | 4-amino-imidazochinolino junginiai | |
| DK3207053T3 (da) | Hidtil ukendte immunogene peptider | |
| IL249823A0 (en) | Meningococcus vaccines | |
| CL2016002146A1 (es) | Plásmidos inmunoestimuladores | |
| BR112016030730A2 (pt) | Composto | |
| DK3129007T3 (da) | Vaccinesammensætninger | |
| EP3560512A4 (en) | COMPOSITION OF VACCINE AGAINST ZONA | |
| FR3025617B1 (fr) | Architecture bi-voies | |
| DK3191466T3 (da) | Azetidinyloxyphenylpyrrolidinforbindelser | |
| HUE053668T2 (hu) | Oltóanyag immunkompromittáltak számára | |
| DK2894265T3 (da) | Pneumatisk aktiveringsindretning | |
| LT3188755T (lt) | Vakcina | |
| BR112016027901A2 (pt) | Compostos | |
| FI20145173L (fi) | Esikammiojärjestely | |
| DE112015004802A5 (de) | Faltvorrichtung | |
| FR3026639B1 (fr) | Composition cosmetique | |
| DE102014117560A8 (de) | Dichtungsprofil | |
| ES1131130Y (es) | Toldo plegable | |
| HUE044999T2 (hu) | Benzofurazán tartalmú anti-amiloid vegyületek | |
| ES1135482Y (es) | Bolardo abatible mejorado | |
| TH1501007869A (th) | องค์ประกอบแชมพู | |
| TH1501005707A (th) | องค์ประกอบแชมพู |